Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | CD81 | P60033 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25347894 | 0.86 | TBXAS1 (0.34) | TBXAS1CD81PPARGEP300 | |
| SCHEMBL8435347 | 0.84 | ALDH1A1 (0.32) | — | |
| SCHEMBL1581278 | 0.84 | TBXAS1 (0.33) | TBXAS1CD81PPARGEP300 | |
| SCHEMBL290896 | 0.84 | TBXAS1 (0.35) | TBXAS1CD81PPARGEP300 | |
| SCHEMBL111604 | 0.84 | TBXAS1 (0.35) | TBXAS1CD81PPARGEP300 | |
| SCHEMBL32685824 | 0.84 | TBXAS1 (0.35) | TBXAS1CD81PPARGEP300 | |
| SCHEMBL22498783 | 0.83 | EP300 (0.33) | TBXAS1CD81PPARGEP300 | |
| SCHEMBL1425197 | 0.82 | TBXAS1 (0.34) | TBXAS1CD81EP300 | |
| SCHEMBL1425200 | 0.82 | TBXAS1 (0.34) | TBXAS1CD81EP300 | |
| Hydrogen Sulfide SCHEMBL379592 | 0.82 | TBXAS1 (0.34) | TBXAS1CD81EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024047952-A1 | POLYMER, FRICTION MODIFIER, LUBRICANT ADDITIVE AND METHOD FOR PRODUCING SAME, AND LUBRICANT | 三菱ケミカル株式会社 | 2024-03-07 | — | — | WO | disclosed |
| EP-4276499-A1 | AIR GAP LAYER, MULTILAYER BODY, METHOD FOR PRODUCING AIR GAP LAYER, OPTICAL MEMBER AND OPTICAL DEVICE | NITTO DENKO CORPORATION (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-3947572-B1 | AQUEOUS COATING COMPOSITION, SUBSTRATE COATED WITH SUCH COMPOSITION, PROCESS FOR CONTROLLING AQUATIC BIOFOULING USING SUCH COATING COMPOSITION | AKZO NOBEL COATINGS INT BV (NL) | 2023-06-07 | — | — | EP | disclosed |
| US-20220177712-A1 | Aqueous Coating Composition, Substrate Coated With Such Composition, Process for Controlling Aquatic Biofouling Using Such Coating Composition | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2022-06-09 | — | — | US | disclosed |
| EP-3947572-A1 | AQUEOUS COATING COMPOSITION, SUBSTRATE COATED WITH SUCH COMPOSITION, PROCESS FOR CONTROLLING AQUATIC BIOFOULING USING SUCH COATING COMPOSITION | Akzo Nobel Coatings International B.V. (NL) | 2022-02-09 | — | — | EP | disclosed |
| EP-3756874-A2 | PINHOLE CONTACT LENS FORMING JIG | Seed Co., Ltd. (JP) | 2020-12-30 | — | — | EP | disclosed |
| WO-2020201213-A1 | AQUEOUS COATING COMPOSITION, SUBSTRATE COATED WITH SUCH COMPOSITION, PROCESS FOR CONTROLLING AQUATIC BIOFOULING USING SUCH COATING COMPOSITION | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2020-10-08 | — | — | WO | disclosed |
| EP-2650021-B1 | MEDICAL DEVICE FOR CONTROLLED RELEASE OF DRUG | SEED CO LTD (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20150299500-A1 | CURABLE COMPOSITION CONTAINING SILICON-CONTAINING HIGHLY-BRANCHED POLYMER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2650021-A1 | MEDICAL DEVICE FOR CONTROLLED RELEASE OF DRUG | Seed Co., Ltd. (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20080177001-A1 | CURABLE COMPOSITIONS | KANEKA CORPORATION (JP) | 2008-07-24 | — | — | US | disclosed |
| US-7388038-B2 | Curable compositions | KANEKA CORPORATION (JP) | 2008-06-17 | — | — | US | disclosed |
| US-20070276066-A1 | Curing Composition | KANEKA CORPORATION (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070225436-A1 | Curable Composition | KANEKA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070167583-A1 | Curable composition | KANEKA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7081494-B2 | Curable compositions | KANEKA CORPORATION (JP) | 2006-07-25 | — | — | US | disclosed |
| US-20060160918-A1 | Curable compositions | KANEKA CORPORATION (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1197498-B1 | METHOD OF TREATING POLYMER | KANEKA CORP (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050131168-A1 | Curable composition and compatibilizing agent | KANEKA CORPORATION (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1197498-A1 | METHOD OF TREATING POLYMER | KANEKA CORPORATION (JP) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160918-A1 | Curable compositions | VCL, VIM, DNMT3L | TBXAS1 1369/4885CD81 3147/4885PPARG 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.